<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37832931</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><Volume>137</Volume><PubDate><Year>2023</Year><Month>Dec</Month></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and safety of concomitant administration of the sabin-strain-based inactivated poliovirus vaccine, the diphtheria-tetanus-acellular pertussis vaccine, and measles-mumps-rubella vaccine to healthy infants aged 18 months in China.</ArticleTitle><Pagination><StartPage>9</StartPage><EndPage>15</EndPage><MedlinePgn>9-15</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2023.10.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(23)00743-9</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">During the COVID-19 pandemic, there was a decline in vaccine coverage, and the implementation of combined vaccines and co-administration strategies emerged as potential solutions to alleviate this predicament. Our objective is to delve into the concurrent administration of the sabin-strain-based inactivated poliovirus vaccine (sIPV), the diphtheria-tetanus-acellular pertussis vaccine (DTaP), and measles-mumps-rubella vaccine (MMR), with the intention of bridging the evidentiary gap pertaining to vaccine co-administration in Chinese infants, and to ensure a safe and effective vaccination strategy, ultimately leading to an augmentation in immunization coverage.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study was a follow-up trial of the "Immunogenicity and safety of concomitant administration of the sIPV with the DTaP vaccine in children: a multicenter, randomized, non-inferiority, controlled trial." Blood samples were collected on day 0 and day 30, and serum antibody levels were detected to measure antibody responses to each of the antigens. Local and systemic adverse events were monitored and compared among groups. This study is the first to fill the knowledge gap in China regarding the safe and effective combined vaccination of sIPV, DTaP, and MMR vaccines.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The geometric mean titer of the poliovirus types I, II, and III neutralizing antibodies were 1060.22 (95% CI: 865.73-1298.39), 1537.06 (95% CI: 1324.27-1784.05), and 1539.10 (95% CI: 1296.37-1827.29) in group I on day 30; geometric mean titer of antibodies against DTaP and MMR in the simultaneous vaccination group was non-inferior to those in the DTaP alone and MMR alone group. Reporting rates of local and systemic adverse reactions were similar between groups and no serious adverse events were reported throughout the clinical study period.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Co-administration of the sIPV, DTaP, and MMR was safe and did not impact immunogenicity, which would help to mitigate administrative costs and enhance vaccine coverage rates.</AbstractText><CopyrightInformation>Copyright Â© 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Haiping</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Binbing</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Expanded Program on Immunization, Anhui Provincial Center for Disease Control and Prevention, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xiaoping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Vaccine research center, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Linyun</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shengyi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Yanhui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, Beijing Institute of Biological Products Company Limited, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, Beijing Institute of Biological Products Company Limited, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shaoxiang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, Chengdu Institute of Biological Products Company Limited, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Long</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, Chengdu Institute of Biological Products Company Limited, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiuling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, Shanghai Institute of Biological Products Company Limited, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Dandan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, Shanghai Institute of Biological Products Company Limited, Shanghai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Expanded Program on Immunization, Anhui Provincial Center for Disease Control and Prevention, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Expanded Program on Immunization, Anhui Provincial Center for Disease Control and Prevention, Hefei, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Vaccine research center, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Xiaoying</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Vaccine research center, Sichuan Provincial Center for Disease Control and Prevention, Chengdu, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cao</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Expanded Program on Immunization, Jiangyou Center for Disease Control and Prevention, Mianyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Pufei</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Expanded Program on Immunization, Jiangyou Center for Disease Control and Prevention, Mianyang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Fenyang</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Xiang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China. Electronic address: sunstone1@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhiguo</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xiaoming</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Medical Affairs Department, China National Biotec Group Company Limited, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022681">Diphtheria-Tetanus-acellular Pertussis Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022542">Measles-Mumps-Rubella Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015721">Diphtheria-Tetanus-Pertussis Vaccine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018073">Haemophilus Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000907">Antibodies, Bacterial</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022681" MajorTopicYN="Y">Diphtheria-Tetanus-acellular Pertussis Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022542" MajorTopicYN="N">Measles-Mumps-Rubella Vaccine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="Y">Poliovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015721" MajorTopicYN="N">Diphtheria-Tetanus-Pertussis Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018073" MajorTopicYN="Y">Haemophilus Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000907" MajorTopicYN="N">Antibodies, Bacterial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Co-administration</Keyword><Keyword MajorTopicYN="N">Diphtheria-tetanus-acellular pertussis vaccine</Keyword><Keyword MajorTopicYN="N">Immunogenicity</Keyword><Keyword MajorTopicYN="N">Inactivated poliovirus vaccine</Keyword><Keyword MajorTopicYN="N">Measles-mumps-rubella vaccine</Keyword><Keyword MajorTopicYN="N">Safety</Keyword></KeywordList><CoiStatement>Declarations of competing interest HC, LL, SW, YX, and XY are employees of the China National Biotec Group. HW and RM are employees of the Beijing Institute of Biological Products. SL and LY are employees of the Chengdu Institute of Biological Products. XL and DC are employees of the Shanghai Institute of Biological Products. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>12</Month><Day>4</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>14</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>13</Day><Hour>19</Hour><Minute>30</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37832931</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2023.10.006</ArticleId><ArticleId IdType="pii">S1201-9712(23)00743-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle>